Human autoimmune disease
POPULARITY
6 episodes with systemic lupus erythematosus
4 episodes with systemic lupus erythematosus
2 episodes with systemic lupus erythematosus
3 episodes with systemic lupus erythematosus
2 episodes with systemic lupus erythematosus
2 episodes with systemic lupus erythematosus
4 episodes with systemic lupus erythematosus
2 episodes with systemic lupus erythematosus
5 episodes with systemic lupus erythematosus
Rheumatoid arthritis, lupus, and Crohn’s disease are autoimmune diseases that share a lot of commonalities. This episode covers when and how they were first recognized and described. Research: Aceves-Avila, Francisco Javier et al. “The Antiquity of Rheumatoid Arthritis: A Reappraisal.” The Journal of Rheumatology 2001; 28:4. Arnaud, Laurent et al. “The History of Lupus Throughout the Ages.” Journal of the American Academy of Dermatology. Volume 87, Issue 6, December 2022. https://www.sciencedirect.com/science/article/abs/pii/S0190962220307726 Barber, Megan R W et al. “Global epidemiology of systemic lupus erythematosus.” Nature reviews. Rheumatology vol. 17,9 (2021): 515-532. doi:10.1038/s41584-021-00668-1 Bornstein, Joseph E. and Randolph M. Steinhagen. “History of Crohn’s Disease.” From Crohn’s Disease: Basic Principles. Springer. 2015. Crohn & Colitis Foundation. “IBD before the Foundation.” https://www.crohnscolitisfoundation.org/about/our-beginning Entezami, Pouya et al. “Historical perspective on the etiology of rheumatoid arthritis.” Hand clinics vol. 27,1 (2011): 1-10. doi:10.1016/j.hcl.2010.09. Geller, Stephen A. and Fernando P F de Camposc. “Crohn disease.” Autopsy Case Rep [Internet]. 2015; 5(2):5-8. http://dx.doi.org/10.4322/acr.2015.001 Hyndman, I.J. (2017), Rheumatoid arthritis: past, present and future approaches to treating the disease. Int J Rheum Dis, 20: 417-419. https://doi.org/10.1111/1756-185X.12823 Kirsner, J B. “Historical origins of current IBD concepts.” World journal of gastroenterology vol. 7,2 (2001): 175-84. doi:10.3748/wjg.v7.i2.175 Laberge, Monique, and Philip E. Koth. "Rheumatoid Arthritis." The Gale Encyclopedia of Medicine, edited by Jacqueline L. Longe, 6th ed., vol. 7, Gale, 2020, pp. 4474-4480. Gale In Context: Science, link.gale.com/apps/doc/CX7986601640/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=8b8ee977. Accessed 30 Apr. 2025. Laurent Arnaud - I6 The history of lupus throughout the ages: Lupus Science & Medicine 2020;7:. https://doi.org/10.1136/lupus-2020-eurolupus.6 org. “The History of Lupus.” https://www.lupus.org/resources/the-history-of-lupus Mandal, Dr. Ananya. “Rheumatoid Arthritis History.” News Medical. 7/7/2023. https://www.news-medical.net/health/Rheumatoid-Arthritis-History.aspx Medical News Today. “The History of Rheumatoid Arthritis.” 5/2/2023. https://www.medicalnewstoday.com/articles/rheumatoid-arthritis-history Michniacki, Thomas. “Crohn’s Disease: An Evolutionary History.” University of Michigan Library. 2006-05 http://hdl.handle.net/2027.42/96969 Potter, Brian. “The History of the Disease Called Lupus.” Journal of the History of Medicine and Allied Sciences , JANUARY 1993, Vol. 48, No. 1 (JANUARY 1993). Via JSTOR. http://www.jstor.com/stable/24622869 Sathiavageesan, Subrahmanian, and Suganya Rathnam. “The LE Cell-A Forgotten Entity.” Indian journal of nephrology vol. 31,1 (2021): 71-72. doi:10.4103/ijn.IJN_249_19 Scofield, R Hal, and James Oates. “The place of William Osler in the description of systemic lupus erythematosus.” The American journal of the medical sciences vol. 338,5 (2009): 409-12. doi:10.1097/MAJ.0b013e3181acbd71 "Systemic Lupus Erythematosus." National Institute of Arthritis and Musculoskeletal and Skin Diseases Pamphlets, National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2001, p. 1. Gale Academic OneFile, link.gale.com/apps/doc/A79512544/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=534bac78. Accessed 30 Apr. 2025. Thomas, Donald E. et al. “The first use of “lupus” as a disease.” Lupus. 2025, Vol. 34(1) 3–9. Tish Davidson, and Rebecca J. Frey. "Crohn's Disease." The Gale Encyclopedia of Medicine, edited by Jacqueline L. Longe, 6th ed., vol. 2, Gale, 2020, pp. 1423-1427. Gale In Context: Science, link.gale.com/apps/doc/CX7986600509/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=2687d598. Accessed 30 Apr. 2025. Van Hootegem, Phillippe. “Is Crohn’s A Rightly Used Eponym?” J Crohns Colitis. 2020 Jul 9;14(6):867-871. doi: 10.1093/ecco-jcc/jjz183. See omnystudio.com/listener for privacy information.
Celebrate Nurses Week starting May 6, 2025! Sign up now at ReMarnurse.com/NursesWeek In this engaging video, Professor Regina Callion, MSN, RN, discusses the critical NCLEX safety points regarding aneurysms. We'll explore what an aneurysm is and why it's crucial for nursing students to understand this topic. Discover the various types of aneurysms, including cerebral, abdominal, and thoracic, and learn how to identify high-risk individuals who need immediate attention. We'll dive into the underlying causes, such as genetic factors and lifestyle choices, and look at the diagnostic tests used, like CT scans and MRIs. You'll also gain insights into management options ranging from monitoring to surgical interventions, along with essential nursing priorities for patient care. Don't forget to like, comment, and subscribe for more informative content on nursing and healthcare topics. Download the ReMar V2 App: ►For iOS: https://apps.apple.com/us/app/remar-v2/id6468063785 ►For Android: https://play.google.com/store/apps/details... ► Find JOBS: http://ReMarNurse.com/jobs ► NCLEX for Africa - http://ReMarNurse.com/KENYA ► Get NCLEX V2: http://www.ReMarNurse.com ►NCLEX V2 Free Trial - http://ReMarNurse.com/free ► FOLLOW ReMar on Instagram: https://www.instagram.com/ReMarNurse/ ► LIKE ReMar on Facebook: https://www.facebook.com/ReMarReview/ ► Subscribe Now on YouTube - http://bit.ly/ReMar-Subscription
In this episode, we review the high-yield topic of Systemic Lupus Erythematosus from the MSK section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets
Season FOUR Episode FIVE of the Your Story Our Fight® podcast welcomes Sheba Family Zaman. As a computer scientist, Sheba has spent the last 20 years working in a technical software role with the quality department of pharmaceutical and life science companies. Her role spans from pre-sales technical information to professional services post-sale with the goal of digitizing critical data that can affect patient safety. She speaks regularly at industry conferences on data integrity and contamination control strategies for aseptic drug manufacturers. She was recently President of non-profit organization – the Parenteral Drug Association, SouthernCalifornia Chapter – for an elected term of 2 years. It is an educational organization dedicated to the connection of science, people, and regulation in a non-bias platform. In June of 2006, Dr. Dan Wallace diagnosed Sheba with Systemic Lupus Erythematosus and Nephritis following struggles with frequent fevers, joint/muscle pain, debilitating fatigue, visibly swollen lymph nodes, and hair loss. Born and raised in Montréal, she soon moved to Southern California to be closer to her family and support system. After grappling with the side effects of strong medications and some tough love counseling from her sister, she started to take her health into her own hands and has spent the last decade avidly reading and educating herself on Lupus and optimal health. Today, Sheba lives in Santa Monica and leads a very active lifestyle as a certified yoga instructor, scuba diver, tennis player, skier, beach volleyball player, runner, and global adventure traveler. She is now working to give back to the community and advocate for Lupus.
Listen as Elizabeth Kircher, DNP, and R. Hal Scofield, MD, discuss best practice approaches for the treatment of Sjögren's syndrome and what's on the horizon for future therapeutic options.Topics include:Challenges in Sjogren's Syndrome Diagnosis and Patient Understanding: Difficulties in explaining Sjogren's syndrome diagnosis to patients unfamiliar with it and challenges in addressing the disease's varied symptomsPatient Education and Communication: Strategies to prevent overwhelming patients during early visits and effective ways to address misconceptionsDiagnostic Challenges and Misunderstandings: Differences between clinical and research criteria for diagnosis and the importance of understanding eachUse of Ultrasound and Biopsy in Diagnosis: Benefits and limitations of ultrasound and biopsies in diagnosing Sjogren's syndromeMultidisciplinary Care Barriers: Challenges in coordinating care among specialists such as ophthalmologists, dentists, and rheumatologistsSymptomatic vs Disease-Modifying Treatments: Strategies for managing symptoms vs addressing the underlying disease with medicationsLong-term Medication and Risks: Considerations when prescribing long-term medications and immunosuppressive therapiesResearch and Emerging Therapies: Developments in Sjogren's syndrome research, including promising medications in clinical trialsGuideline Development and Patient Reassurance: The role of professional guidelines in shaping care and providing patients with reassurancePolypharmacy and Medication Reconciliation: The importance of pharmacist involvement in managing complex medication regimens for older patients Faculty:Elizabeth Kircher, DNPR. Hal Scofield, MDMember/Professor, Arthritis & Clinical ImmunologyOklahoma Medical Research FoundationProfessor, Department of Medicine, College of MedicineUniversity of Oklahoma Health Sciences CenterAssociate Chief of Staff for ResearchOklahoma City US Department of Veterans Affairs Medical CenterOklahoma City, OklahomaLink to full program:https://bit.ly/3YKpsOE
In another installment in the ongoing Arthritis & Rheumatology immunology series, guest David S. Pisetsky, MD, PhD, author of Unique Interplay Between Antinuclear Antibodies and Nuclear Molecules in the Pathogenesis of Systemic Lupus Erythematosus, takes us on a deep dive into research in SLE on how the combination of ANAs and immunologically active DNA can create new structures that can promote inflammation throughout the body as well as drive organ inflammation and damage.
This week, our next guest, ACR Master Dr. Joan T. Merrill, joins us to discuss her latest study which endeavored to evaluate the efficacy and safety of upadacitinib and elsubrutinib in those with systemic lupus erythematosus (SLE). Join us for an in-depth analysis of the SLEek Study, its findings regarding the efficacy of these medications and Dr. Merrill's conclusions.
This week, our next guest, ACR Master Dr. Joan T. Merrill, joins us to discuss her latest study which endeavored to evaluate the efficacy and safety of upadacitinib and elsubrutinib in those with systemic lupus erythematosus (SLE). Join us for an in-depth analysis of the SLEek Study, its findings regarding the efficacy of these medications and Dr. Merrill's conclusions.
Cindy Hutchens describes her experiences living with SLE and her interactions with the healthcare system along the way. Resources & References 1) Lupus Foundation of America (LFA) 2) The Lupus Book by Daniel Wallace 3) LFA Mid-South Chapter, Nashville, TN 4) LFA Walk to End Lupus Now 5) Jog NR, James JA. Epstein Barr Virus and Autoimmune Responses in Systemic Lupus Erythematosus. Front Immunol. 2021 Feb 3;11:623944. doi: 10.3389/fimmu.2020.623944. PMID: 33613559; PMCID: PMC7886683. 6) Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016 Jun;3(2):75-84. doi: 10.5152/eurjrheum.2015.0085. Epub 2015 Dec 29. PMID: 27708976; PMCID: PMC5042235. 7) Benlysta prescribing information 8) Rexulti prescribing information 9) Aplenzin prescribing information
For those with rheumatic disease, everyday challenges can mean an increase in disease flare. However, research is increasingly pointing to the idea that psychosocial stressors could even heighten the risk of developing rheumatic diseases. Dr. Christine Parks looked deeper into this among those with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) in her latest study Life Events, Caregiving, and Risk of Autoimmune Rheumatic Diseases in the Women's Health Initiative Observational Study
Learn about the importance of reducing organ damage and corticosteroid-associated toxicity in SLE, and how biologics may help to change the course of the disease by targeting its underlying mechanisms.
Vinetta started her healing journey back in 2013, after struggling with Systemic Lupus Erythematosus, Sjogren's syndrome, chronic fatigue syndrome and other associated conditions since 1998. She shares with me how she healed herself, what her Rheumatologist shared with her and how she found that the illnesses were serving her. 00:00 Introduction 01:02 Healing Lupus 08:12 Lightbulb moment 14:07 Interesting visit with Rheumatologist 19:50 Hydroxychloroquine information 22:49 Lupus as a barometer 29:07 Holding shame for illness 35:06 Group support 38:06 Do you want to get well? Vinetta´s bio and contact information. Having failed to conquer her condition, she sought the support of a Naturopath. It was the first time she had been able to really speak candidly about the difficulties she had been facing with the debilitating aspects of the disease, particularly the lack of energy. With the help of her naturopath she was able to review her diet and lifestyle and look at natural remedies that would help support her. The main culprit seemed to be gluten, once this was removed a gradual increase in energy returned and she noticed a significant reduction in phlegm and throat issues. The diet was just the springboard and created the right ecosystem to look at her life holistically. Vinetta trained with a Reiki master and started practicing Reiki regularly to help heal the less visible aspects of her condition, she began to listen daily to Louise Hay and her “You can heal your life” philosophy, as well as dipping into self-help books, practising yoga, kinesiology treatments and meditation practice. Fast forward to 2024, going against medical advice in a bid to free her body from the toxins of over 20 years of taking medications, Vinetta weaned herself off medications for good. Today, Vinetta no longer takes any medications, and her Rheumatologist was quite shocked and confused by the transformation in her health and reluctantly confirmed that the disease is in remission. Years of battling with joint pains, Sjogren's syndrome, joint swelling, gut issues and chronic fatigue are finally a thing of the past. She now has energy to live a full and more rewarding life including running a cosmetic and homecare business with her husband. https://www.linkedin.com/in/vinettabrewdirectorregulatorycompliancehere2grow/
The story is about a woman entangled in material things instead of wanting a simple life. Dove's parents are both servants of the Lord and in her childhood years they lived a simple life. Still, when Dove had a chance to stay in Manila to pursue studies and a career, she got an uncommon disease which is called “Systemic Lupus Erythematosus”-an autoimmune disease that causes hair loss, butterfly rash, joint pain and severe weaknesses of the body. Support CBN Asia today!https://www.cbnasia.com/giveSupport the Show.
Systemic lupus erythematosus (SLE) can present at any age and is associated with immune-mediated damage to multiple organs and increased rates of cardiovascular disease, cancer, and disability. New treatments have been FDA approved. Caroline H. Siegel, MD, MS, discusses this and more with JAMA Deputy Editor Mary McGrae McDermott, MD. Related Content: Systemic Lupus Erythematosus
Hear Dr. Richard Furie and Dr. Leanna Wise discuss clinical considerations related to the 2023 EULAR treatment recommendations for SLE. US-85292 last updated 2/24.
Embark on an enlightening exploration of systemic lupus erythematosus (SLE) with the insightful Dr. Shah on MedEvidence. We delve deep into the perplexing world of lupus, shedding light on its signature symptoms like the striking malar rash, while clarifying common misconceptions to foster a better understanding of this enigmatic condition. Beyond its cutaneous manifestations, we discuss how lupus can affect multiple organs and the significance of genetic predisposition, offering a comprehensive look at why this disease remains a formidable challenge in the medical community.Navigating the lupus diagnosis and management maze can be as complex as the disease itself. Join us as we dissect early warning signs, from the elusive fatigue and Raynaud's phenomenon to more overt cues that may often be mistaken for less serious health issues. With Dr. Shah's guidance, we reveal the intricacies of the diagnostic process, emphasizing the necessity of a multifaceted treatment strategy. We don't hold back on discussing the potential complications of lupus, particularly when it comes to pregnancy, underscoring the critical nature of vigilant disease management.As we move towards a future filled with medical advancements, we share a message of hope for those living with lupus. We cover the gamut of treatment options, from the tried-and-true hydroxychloroquine to the breakthrough potential of JAK inhibitors, and offer practical tips for day-to-day living with lupus. Our conversation ultimately culminates with an invitation for listeners to join forces in the ongoing quest for autoimmune disease research breakthroughs, empowering you to become an active participant in the journey towards a brighter, healthier future.Lupus Snapshot:
As the year winds down and a new year is about to begin, looking back sometimes forces us to look ahead. Last month's Convergence 2023 offered an opportunity to do just that: Look Ahead! We've invited the two speakers from the “The Clinical Year in Preview” session, Joan Bathon, MD and Jill Buyon, MD to discuss with us the latest abstracts that are expected to make the biggest waves in the coming year, as they relate to Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). We discuss a variety of abstracts that include the use of AI, steroid use, hydroxychloroquine dosing, preventing the development of RA in lupus, pregnancy in lupus dosing for methotrexate and much, much more.
Ronald F. van Vollenhoven, MD, PhD - Key Updates on the Treatment Paradigm for Systemic Lupus Erythematosus
Dr. Amy Valent engages in an insightful conversation with Dr. Sarah Osmundson, author of SMFM Consult #64. They delve into the complexities of systemic lupus erythematosus and pregnancy. Dr. Osmundson provides expert insight, addressing maternal and fetal complications, medication management, and crucial considerations for expectant mothers with lupus. Tune in to this episode to explore the unique challenges of lupus in pregnancy. The full transcript can be found at this link.
This episode covers systemic lupus erythematosus.Written notes can be found at https://zerotofinals.com/medicine/rheumatology/sle/ or in the rheumatology section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.
Photosensitivity among patients with SLE is a well-known symptom. However, what is not well-known is why. Our guest this week, Dr. J. Michelle Kahlenberg MD, PhD and team, endeavored to uncover that answer. The article, “Regulation of Photosensitivity by the Hippo Pathway in Lupus Skin” was the result of this study, which was published in “Arthritis & Rheumatology” earlier this year. Dr. Kahlenberg joins us for this episode to discuss the study's methods, results and its surprising conclusion: a novel driver was discovered!
Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and fitness updates! Learn more about your ad choices. Visit megaphone.fm/adchoices
Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and fitness updates! Learn more about your ad choices. Visit megaphone.fm/adchoices
Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and fitness updates! Learn more about your ad choices. Visit megaphone.fm/adchoices
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Amrie Grammer and Dr. Peter Lipsky from AMPEL BioSolutions. Together they describe the molecular endotypes of Type 1 and Type 2 Systemic Lupus Erythematosus. This episode uncovers the distinct molecular profiles of these SLE types and paves the way for personalized treatment approaches based on these classifications. Link to published paper: https://lupus.bmj.com/content/10/1/e000861
Join experts Drs Matt Sparks and Dawn Caster as they discuss the complexities around the management of lupus nephritis. What tools do we have now? What is on the horizon? Tune in to find out. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991602). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Novel Aspects in the Pathophysiology and Diagnosis of Glomerular Diseases https://pubmed.ncbi.nlm.nih.gov/36535746/ Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus https://pubmed.ncbi.nlm.nih.gov/22553077 EULAR/ACR Classification Criteria for SLE https://pubmed.ncbi.nlm.nih.gov/31779843/ Sensitivity and Specificity of ANA and Anti-dsDNA in the Diagnosis of Systemic Lupus Erythematosus: A Comparison Using Control Sera Obtained From Healthy Individuals and Patients With Multiple Medical Problems https://pubmed.ncbi.nlm.nih.gov/24383972/ Podocyte Foot Process Effacement Precedes Albuminuria and Glomerular Hypertrophy in CD2-Associated Protein Deficient Mice https://pubmed.ncbi.nlm.nih.gov/34568396/ KDIGO 2023 Clinical Practice Guideline for the Management of Lupus Nephritis https://kdigo.org/wp-content/uploads/2023/03/KDIGO-2023-Lupus-Nephritis-Guideline_Public-Review_9-Mar-2023.pdf Management of Lupus Nephritis: A Systematic Literature Review Informing the 2019 Update of the Joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) Recommendations https://pubmed.ncbi.nlm.nih.gov/32699043/ Nonrenal Disease Activity Following Mycophenolate Mofetil or Intravenous Cyclophosphamide as Induction Treatment for Lupus Nephritis: Findings in a Multicenter, Prospective, Randomized, Open-Label, Parallel-Group Clinical Trial https://pubmed.ncbi.nlm.nih.gov/20039429/ Immunosuppressive Therapy in Lupus Nephritis: The Euro-Lupus Nephritis Trial, a Randomized Trial of Low-Dose Vs High-Dose Intravenous Cyclophosphamide https://pubmed.ncbi.nlm.nih.gov/12209517/ Voclosporin: A Novel Calcineurin Inhibitor for the Treatment of Lupus Nephritis https://pubmed.ncbi.nlm.nih.gov/35168373 Safety and Efficacy of Belimumab in Patients With Lupus Nephritis: Open-Label Extension of BLISS-LN Study https://pubmed.ncbi.nlm.nih.gov/36302567/ Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus https://pubmed.ncbi.nlm.nih.gov/36109639/ Dapagliflozin in People With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/37257897/ Empagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/36331190/
Our guest this week is Dr. April Barnado, the first author of a study which analyzed a cohort of 3.2 million patients with Systemic Lupus Erythematosus (SLE), during pregnancy, from 1989 to 2020. Her team's work, titled “Systemic Lupus Erythematosus Delivery Outcomes Are Unchanged Across Three Decades“ was published in “ACR Open Rheumatology”, and found some amazing trends regarding outcomes of the pregnancies and even in medication use. The study, its methods, conclusions and Dr. Barnado's advice on breaking into academic research, is the focus of our show.
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Ian Bruce, from the University of Manchester in the UK. Dr Bruce discusses the time to onset of clinical response to Anifrolumab in patients with Systemic Lupus Erythematosus. The episode delves into pooled data from two significant Phase III trials, TULIP-1 and TULIP-2, offering listeners a deep understanding of the effectiveness and timeline of Anifrolumab treatment. Read the article: http://dx.doi.org/10.1136/lupus-2022-000761
In this episode our host Dr Raquel Faria discusses research insights and best practices as presented at the Lupus and KCR 2023 Meeting with Prof Sandra Navarra and Prof Ronald van Vollenhoven of the Lupus Academy Steering Committee. You can link through here to the full report on the 15th International Congress on Systemic Lupus Erythematosus in our library. Disclaimer: ‘During Lupus Academy podcast episodes, participants may refer to off label use of medicines for patients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.'
Is it a rash or a wolf bite? Apparently ancient physicians couldn't tell…or at least they thought that the classic rash across the faces of patients with the commonly known condition Lupus, looked close enough to a wolf's bite to name it after the Latin word for wolf! We'll be discussing Systemic Lupus Erythematosus, or Lupus, on this episode, including some history and common symptoms that feel a little random and are what make Lupus so hard to diagnose. Then we'll talk about its prevalence in women and some interesting theories on why its so common in women over men! Join the From Skirts To Scrubs community and meet us at the intersection of feminism, medicine, and history!Follow us on socials:Instagram: @fromskirtstoscrubs Facebook: @fromskirtstoscrubs TikTok: @fromskirtstoscrubsTwitter: @FSTS_Podcast
Live Nursing Review with Regina MSN, RN! Every Monday & Wednesday we are live. LIKE, FOLLOW, & SUB @ReMarNurse for more. Sign up for the NCLEX 30-Day Challenge Review now at http://www.ReMarNurse.com/30Days Quick Facts for NCLEX Next Gen Study Guide here - https://bit.ly/QF-NGN Study with Professor Regina MSN, RN every Monday as you prepare for NCLEX Next Gen. ► Create Free V2 Account - http://www.ReMarNurse.com ► Get Quick Facts Next Gen - https://bit.ly/QF-NGN ► Subscribe Now - http://bit.ly/ReMar-Subscription ► GET THE PODCAST: https://remarnurse.podbean.com/ ► WATCH LESSONS: http://bit.ly/ReMarNCLEXLectures/ ► FOLLOW ReMar on Instagram: https://www.instagram.com/ReMarNurse/ ► LIKE ReMar on Facebook: https://www.facebook.com/ReMarReview/ ReMar Review features weekly NCLEX review questions and lectures from Regina M. Callion MSN, RN. ReMar is the #1 content-based NCLEX review and has helped thousands of repeat testers pass NCLEX with a 99.2% student success rate! ReMar focuses on 100% core nursing content and as a result, has the best review to help nursing students to pass boards - fast!
4.04 Systemic Lupus Erythematosus Rheumatology review for the USMLE Step 1 Exam Marfan's syndrome, Ehlers-danlos, and homocystinuria are three distinct diseases that affect connective tissue. They share some clinical features like tall stature, long fingers, scoliosis, high arched pallet, chest wall deformities, joint hypermobility, and lens dislocation. Marfans is caused by a mutation in the FBN1 gene, resulting in defective fibrillin-1, and the main complication is aortic root dilation. Homocystinuria is a metabolic disorder caused by a defect in homocysteine breakdown, leading to elevated levels of homocysteine, and the main complication is thrombosis. Ehlers-Danlos is caused by a deficiency in type III collagen, and the main complication is vascular rupture. Marfans has an upward lens dislocation, homocystinuria has a downward lens dislocation, and Ehlers-Danlos has hyperextensible skin and joint hyperextensibility. Marfans usually presents in teens, homocystinuria in children, and Ehlers-Danlos in young adults. Patient presentations: Marfans - scoliosis, long fingers, and caved in chest wall in a tall teen; Homocystinuria - developmental delay, long fingers, and tall stature in a child; Ehlers-Danlos - recurrent bruising, hyper extensible skin, and joint hyperextensibility in a young adult.
Nick and Fei come back for the second part of SLE in pregnancy. How do we manage lupus in pregnancy? What do we do about flares? Remember to sign up for the Ob/Gyn Intern Challenge, which starts on May 1! Check out the website for the Rosh Review question of the week. Twitter: @creogsovercoff1 Instagram: @creogsovercoffee Facebook: www.facebook.com/creogsovercoffee Website: www.creogsovercoffee.com Patreon: www.patreon.com/creogsovercoffee You can find the OBG Project at: www.obgproject.com
Nick and Fei discuss lupus in pregnancy. What is it? How is it diagnosed? And how does it affected pregnancy? *Apologies for the audio quality today -- Fei is in a new space and still figuring out how to best adjust for it! Twitter: @creogsovercoff1 Instagram: @creogsovercoffee Facebook: www.facebook.com/creogsovercoffee Website: www.creogsovercoffee.com Patreon: www.patreon.com/creogsovercoffee You can find the OBG Project at: www.obgproject.com
In this podcast, expert clinicians will review a challenging case of systemic lupus erythematosus and discuss new or emerging therapeutic options that may be of benefit.
Do you plan to work past the age of seventy? Linda Ruescher is already doing that six days a week and she does it with Systemic Lupus Erythematosus (the most common type of lupus). It is a condition that we will explain today along with many other things that make this such a special lady. Guest Bio: Linda Ruescher is committed to leaving this world a little better than she found it. She is a pastoral musician who helps people deepen their experience of the divine through inspiring music and well prepared liturgies for all ages. Guest Contact Info: Blog http://copingwithchronicillness.blogspot.com/ Web www.copingwithchronicillness.com Amazon http://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Daps&field-keywords=linda+ruescher Facebook: https://www.facebook.com/Linda-Ruescher-658216417599351/ Twitter: https://www.linkedin.com/in/linda-ruescher-a3271410/ LinkedIn: https://www.linkedin.com/in/linda-ruescher-a3271410/ YouTube: https://www.youtube.com/c/LindaRuescher Thanks for listening to the show! It means so much to us that you listened to our podcast! If you would like to continue the conversation, please email me at allen@drallenlycka.com or visit our Facebook page at http://www.facebook.com/drallenlycka. We would love to have you join us there, and welcome your messages. We check our Messenger often. If you loved the podcast, be sure to subscribe on your favorite platform, share it with friends and leave a review! Dr. Lycka wants you to live your best life. Visit coachingwithdrlycka.com and book your Discovery call today. His bestselling book, "The Secrets to Living a Fantastic Life" can be found on Amazon.com. Get your copy today! We are building a community of like-minded people in the personal development/self-help/professional development industries, and are always looking for wonderful guests for our show. If you have any recommendations, please email us! Dr. Allen Lycka's Social Media Links Facebook: http://www.facebook.com/drallenlycka Instagram: https://www.instagram.com/dr_allen_lycka/ Twitter: https://www.twitter.com/drallenlycka LinkedIn: https://www.linkedin.com/in/allenlycka YouTube: https://www.YouTube.com/c/drallenlycka Subscribe to the podcast We would be honored to have you subscribe to the How to Live a fantastic Life show – you can subscribe to the podcast app on your mobile device. Leave a review We appreciate your feedback, as every little bit helps us produce even better shows. We want to bring value to your day, and have you join us time and again. Ratings and reviews from our listeners not only help us improve, but also help others find us in their podcast app. If you have a minute, an honest review on iTunes or your favorite app goes a long way! Thank you!
In this episode, Jonathan is joined by Chris Wincup, Versus Arthritis Clinical Research Fellow in Rheumatology, Department of Rheumatology, University College London, UK. They discuss the current treatments for systemic lupus erythematosus (SLE), as well as symptoms. They also consider mental health in patients with SLE, and the effect that the COVID-19 pandemic has had on patients with SLE and autoimmune diseases.
When assessing the integument of a patient with systemic lupus erythematosus, which of the following skin changes will MOST likely be present? Find it all out in this podcast! Be prepared for the NPTE so that you can pass with flying colors! Check out www.ptfinalexam.com/podcast for more information and to stay up-to-date with our latest courses and projects.
In this episode our host, Dr Raquel Faria, is joined by Professors Ricard Cervera and Zahir Amoura who will be providing expert insights from the key lupus research in 2022. For the full written report '2022 Year in Review' please refer to our online library: https://www.lupus-academy.org/library/congress-reports Disclaimer: ‘During Lupus Academy podcast episodes, participants may refer to off label use of medicines for patients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.' References for this episode: Bruce IN, Furie RA, Morand EF, et al. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022;81(7):962-969. Dörner T, van Vollenhoven RF, Doria A, et al. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Res Ther. 2022;24(1):112. Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100-107. Furie RA, Hough DR, Gaudy A, et al. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. 2022;9(1). Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus. N Engl J Med. 2022 Sep 8;387(10):894-904. Ginzler E, Guedes Barbosa LS, D'Cruz D, et al. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022;74(1):112-123. Jayne D, Rovin B, Mysler EF, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496-506. Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H, Zhao F, Yu H, Qiu L, Li X, He X, Chen Y, Xu Z, Xu H. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial. Lupus. 2022 Jul;31(8):998-1006. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study. J Rheumatol. 2022;49(4):380-387.
Better Edge : A Northwestern Medicine podcast for physicians
Despite a prevalence of over 50% among patients with systemic lupus erythematosus (SLE), neuropsychiatric symptoms of SLE (NP-SLE), including anxiety and movement disorders, have not been well understood. The paucity of data examining underlying mechanisms is what spurred the work of Carla M. Cuda, PhD, pointing to microglia as a driver of disease.Dr. Cuda, who is assistant professor of Rheumatology at Northwestern Medicine, and other Northwestern Medicine investigators were the first to show that microglial expression of disease-associated microglia (DAM)-associated genes correlates with the severity of hippocampal- and cerebellar-associated behavioral deficits in an NP-SLE model prior to overt systemic disease. While DAM have been extensively studied in Alzheimer's disease, no studies have specifically examined DAM in NP-SLE, until now.
In this episode, Dr. Shanmugam discusses “A Randomized, Placebo-controlled Phase 3 Extension Trial of Long-term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus”, a three-year long-term study designed to understand the safety of anifrolumab in patients with systemic lupus erythematosus (SLE). This study, which was recently published in “Arthritis & Rheumatology”, represents the longest placebo-controlled clinical trial performed in SLE to date. She is joined by our guest, Dr. Richard Furie, Chief of the Division of Rheumatology at Northwell Health in New York and co-author of the paper.
Season TWO Episode FOURTEEN of the Your Story Our Fight® podcast welcomes Cambria Francesca. Life plans were sidelined when she woke up one night to an excruciating pain. A constant pain that she has now grown so accustom to that she no longer remembers what it felt like to be painless. Having a sister with SLE and a father with Discoid, Cambria's mother knew that there's 11 criteria for a Lupus diagnosis and that a low white blood cell count falls under one of them. They ran tests and confirmed, she has Systemic Lupus Erythematosus.While recovering in the ICU, after other illness had threatened her life, she used her trauma and pain as inspiration to pursue a career as a plus size model. Fast forward a little over a year and Cambria has become Plus Model Magazine's Model of the Month for their March 2016 issue. That same year, she was chosen to walk for Full Figure Fashion Week. Now, 6 years later, Cambria gets to work with brands who are inspired by the diversity of the world we live in.
Dr. Aixa Goodrich has been a good friend and colleague for a long time and I have interviewed her on multiple occasions. Her passion and expertise are valuable and she is easy to listen to.Dr. Goodrich has been leading people to a healthier way of life for nearly 25 years. Shifting people's perspectives from Crisis Care to Lifestyle Care is her expertise. She has been a key member of The 100 Year Lifestyle Network of Chiropractors for more than a decade.In this episode, Dr. Goodrich ad I discuss...What to do if you have a serious health crisisHow do you make the transition from simply recovering to optimum healthWhat should you do if your doctor is negative and gives you no hopeImportant questions that stimulate thoughts regarding health and healingResources to get you away from a lifetime of prescription drugsMuch moreDr. Goodrich received a Bachelor of Science in Human Biology from Logan College and a Doctorate from Logan College of Chiropractic. In 1998, she was selected as “Who's Who Among Students in American Colleges & Universities” for her academics and persona. The Journal of Neuromuscular Systems recognized her dedication to health and wellness by publishing her work on Grand Round Discussion on Systemic Lupus Erythematosus.Today, Dr. Aixa Goodrich treats patients of all ages, including infants and seniors, which has given her a wealth of experience, allowing her to fit her patients' needs best. With a commitment to providing quality care through a culture of caring and excellence, Dr. Aixa Goodrich has completely redefined the health and wellness experience of those she serves.She is certified in Whole-Foods and Plant-based nutrition from Cornell University and is a Certified Functional Medicine Practitioner.Dr. Goodrich practices in the Miami area and can be reached at South Florida Chiropractic and Wellness Center.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/XJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic lupus erythematosus (SLE) is an autoimmune disease associated with substantial morbidity and mortality, especially in women. The disease causes progressive damage to multiple organ systems and reduces quality of life. Improving your understanding of SLE heterogeneity at the clinical and mechanistic level can drive significant improvements across the care spectrum. In this expert-driven activity, you will hear the latest clinical evidence presented during the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress in Copenhagen, Denmark, with regard to the current treatment options for SLE and the potential for TYK2 inhibitors to change SLE management. Upon completion of this activity, participants should be better able to: Recognize the burden of SLE and the impact of delayed or suboptimal treatment on patient outcomes; Describe the mechanistic rationale and recent safety and efficacy data supporting a role for targeting TYK2 and BTK as potential therapeutic approaches in SLE; and Identify SLE patients who might benefit from emerging TYK2 and BTK inhibition strategies through clinical trial enrollment and recognizing potential implications for a future treatment paradigm.
Go online to PeerView.com/XJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic lupus erythematosus (SLE) is an autoimmune disease associated with substantial morbidity and mortality, especially in women. The disease causes progressive damage to multiple organ systems and reduces quality of life. Improving your understanding of SLE heterogeneity at the clinical and mechanistic level can drive significant improvements across the care spectrum. In this expert-driven activity, you will hear the latest clinical evidence presented during the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress in Copenhagen, Denmark, with regard to the current treatment options for SLE and the potential for TYK2 inhibitors to change SLE management. Upon completion of this activity, participants should be better able to: Recognize the burden of SLE and the impact of delayed or suboptimal treatment on patient outcomes; Describe the mechanistic rationale and recent safety and efficacy data supporting a role for targeting TYK2 and BTK as potential therapeutic approaches in SLE; and Identify SLE patients who might benefit from emerging TYK2 and BTK inhibition strategies through clinical trial enrollment and recognizing potential implications for a future treatment paradigm.
Dr. Ryan M. Militana discusses “Current Considerations in Management of Systemic Lupus Erythematosus in the Parturient.”
In this episode, listen as Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, answer key questions about identifying patients at high risk for lupus nephritis, whether an elevated serum creatinine always signals lupus nephritis, the safety of newer therapies for lupus in women who are pregnant or breastfeeding, and the possibility of using SGLT2 inhibitors in patients with lupus nephritis.Presenters: Karen H. Costenbader, MD, MPHProfessor of MedicineDepartment of MedicineHarvard Medical SchoolDirector, Lupus ProgramDivision of Rheumatology, Inflammation and ImmunityBrigham and Women's HospitalBoston, MassachusettsBrad H. Rovin, MDProfessor and Director, Division of NephrologyThe Lee A. Hebert Professor of NephrologyMedical Director, The Ohio State Center for Clinical Research ManagementThe Ohio State University Wexner Medical CenterColumbus, OhioReview the downloadable slidesets at: https://bit.ly/3mlHOlaLink to full program:https://bit.ly/3aC2NNL
In this episode, Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, discuss health disparities in systemic lupus erythematosus and lupus nephritis. Topics include: Disproportionate prevalence among marginalized groups in the United StatesLupus-related social determinants of healthChallenges with medication adherenceStrategies to reduce these disparitiesPresenters:Karen H. Costenbader, MD, MPHProfessor of MedicineDepartment of MedicineHarvard Medical SchoolDirector, Lupus ProgramDivision of Rheumatology, Inflammation and ImmunityBrigham and Women's HospitalBoston, MassachusettsBrad H. Rovin, MDProfessor and Director, Division of NephrologyThe Lee A. Hebert Professor of NephrologyMedical Director, The Ohio State Center for Clinical Research ManagementThe Ohio State University Wexner Medical CenterColumbus, OhioThis episode is part of a larger program titled, “Lupus and Lupus Nephritis: Improving Outcomes and Reducing Disparities.” To access the full program, follow this link: https://bit.ly/3PWAzNU
The ABMP Podcast | Speaking With the Massage & Bodywork Profession
A client has a bewildering collection of signs and symptoms: hard, swollen ankles, a stiff elbow, fingers that “reverse direction”—what on earth is going on? It's lupus, an autoimmune disease that can affect virtually every system in the body. It's not always serious, but some of the consequences of the disease and of treatments for it have big repercussions for massage therapy clinical decisions. Sponsors: Books of Discovery: www.booksofdiscovery.com Host Bio: Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com. Recent Articles by Ruth: “Unpacking the Long Haul,” Massage & Bodywork magazine, January/February 2022, page 35, www.massageandbodyworkdigital.com/i/1439667-january-february-2022/36. “Chemotherapy-Induced Peripheral Neuropathy and Massage Therapy,” Massage & Bodywork magazine, September/October 2021, page 33, http://www.massageandbodyworkdigital.com/i/1402696-september-october-2021/34. “Pharmacology Basics for Massage Therapists,” Massage & Bodywork magazine, July/August 2021, page 32, www.massageandbodyworkdigital.com/i/1384577-july-august-2021/34. Resources: Pocket Pathology: https://www.abmp.com/abmp-pocket-pathology-app Aringer, M. et al. (2019) ‘2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus', Arthritis & Rheumatology, 71(9), pp. 1400–1412. doi:10.1002/art.40930. Diagnosing Lupus - What is Lupus | Lupus Research Alliance (no date) Lupus Research. Available at: https://www.lupusresearch.org/understanding-lupus/what-is-lupus/diagnosis/. González, L.A. et al. (2013) ‘Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes', Lupus, 22(12), pp. 1214–1224. doi:10.1177/0961203313502571. ‘Lupus Update 2021: Classification Criteria, Disease Activity Measures & More' (no date) The Rheumatologist. Available at: https://www.the-rheumatologist.org/article/lupus-update-2021-classification-criteria-disease-activity-measures-more/.
© 2020-2025 Ivy Podcast Discovery LLC
